GleamWall
中文EN

GNPX Genprex, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595248 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-233.7%
ROA-160.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets21.7%
Debt / equity0.00x
Current ratio4.26x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.74M$2.68M$2.75M$2.20M$2.19M$2.50M$2.54M$2.84M
SG&A expense$1.53M$1.80M$1.75M$1.32M$1.15M$2.18M$1.43M$1.50M
Operating income-$4.27M-$4.48M-$4.49M-$3.52M-$3.35M-$4.68M-$3.97M-$4.34M
Net income-$4.24M-$4.45M-$4.46M-$3.79M-$3.80M-$4.67M-$3.96M-$4.33M
EBITDA——-$4.49M-$3.52M-$3.35M-$4.68M-$3.97M-$4.34M
EPS (basic)-5.30-9.40-0.64—-109.39-185.30-12.98—
EPS (diluted)————————
Balance sheet
Cash & equivalents$15.35M$15.15M$18.05M$7.83M$1.10M$1.35M$3.47M$1.60M
Current assets$16.19M$15.84M$18.80M$8.36M$1.72M$2.06M$4.16M$2.08M
PP&E, net———$0———$0
Intangibles———————$0
Total assets$17.52M$17.14M$20.31M$10.16M$3.56M$3.83M$6.01M$4.12M
Current liabilities$3.80M$2.34M$3.35M$2.17M$2.55M$2.44M$2.14M$2.50M
Total liabilities$3.80M$2.34M$3.38M$2.20M$2.79M$2.44M$2.14M$2.50M
Shareholders' equity$13.72M$14.80M$16.93M$7.96M$767,808$1.39M$3.87M$1.62M
Shares outstanding1.22M506,2189.04M149,8111.00M33.15M24.15M217,234
Cash flow statement
Operating cash flow-$2.94M-$5.14M-$3.14M-$4.10M-$3.19M-$3.86M-$4.16M-$3.87M
Investing cash flow———$0$0$0$0-$1
Financing cash flow$3.13M$2.24M$13.36M$10.83M$2.94M$1.74M$6.03M$3.98M
Depreciation & amortization——$0$0$0$0$0$463
Stock-based compensation$40,000$68,354$118,634-$363,243$20,000$458,918$184,773$265,034

Free plan shows the latest 8 periods; Pro shows all 41 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.